Advanced search
Publication Cover
Annals of Medicine Volume 47, 2015 - Issue 5
Submit an article Journal homepage
1,181
Views
61
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease

Sha LiDivision of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing100037, China
,
Yan ZhangDivision of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing100037, China
,
Rui-Xia XuDivision of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing100037, China
,
Yuan-Lin GuoDivision of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing100037, China
,
Cheng-Gang ZhuDivision of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing100037, China
,
Na-Qiong WuDivision of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing100037, China
,
Ping QingDivision of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing100037, China
,
Geng LiuDivision of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing100037, China
,
Qian DongDivision of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing100037, China
&
Jian-Jun LiDivision of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing100037, ChinaCorrespondence[email protected]
 show all
Pages 386-393 | Received 17 Dec 2014, Accepted 14 Apr 2015, Published online: 08 Jul 2015

Citations (61)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Xiaoxiao Zhao, Li Song, Ying Wang, Jiannan Li, Jinying Zhou, Runzhen Chen, Chen Liu, Peng Zhou, Zhaoxue Sheng, Yi Chen, Hanjun Zhao & Hongbing Yan. (2021) Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI. Journal of Inflammation Research 14, pages 5319-5335.
Read now

Articles from other publishers (60)

Qin Luo, Zhenchu Tang, Panyun Wu, Zhangling Chen, Zhenfei Fang & Fei Luo. (2023) A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022. Frontiers in Endocrinology 14.
Crossref
Chi Chiu Mok, Ling Yin Ho, Kar Li Chan, Sau Mei Tse & Chi Hung To. (2023) Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Associated with Disease Activity and Risk of Incident Cardiovascular Disease in Patients with Systemic Lupus Erythematosus. Inflammation 46:4, pages 1458-1470.
Crossref
Ignatios Ikonomidis, Konstantinos Katogiannis, Christina Chania, Nikolaos Iakovis, Maria Tsoumani, Andriana Christodoulou, Evangelia Brinia, George Pavlidis, John Thymis, Damianos Tsilivarakis, Aikaterini Kountouri, Emmanouil Korakas, Vaia Lambadiari, Filippos Triposkiadis, Leandros Skaltsounis, Ioulia Tseti, Efstathios K. Iliodromitis & Ioanna Andreadou. (2023) Association of hydroxytyrosol enriched olive oil with vascular function in chronic coronary disease. European Journal of Clinical Investigation 53:7.
Crossref
Minglu Ma, Chang Hou & Jian Liu. (2023) Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation. Frontiers in Cardiovascular Medicine 10.
Crossref
Tadeja Sotler & Miran Šebeštjen. (2023) PCSK9 as an Atherothrombotic Risk Factor. International Journal of Molecular Sciences 24:3, pages 1966.
Crossref
Sandeep Banga, Jagadeesh K. Kalavakunta, Oliver Abela & On Topaz. 2023. Cholesterol Crystals in Atherosclerosis and Other Related Diseases. Cholesterol Crystals in Atherosclerosis and Other Related Diseases 351 374 .
Ioannis Dafnis, Aikaterini N. Tsouka, Christina Gkolfinopoulou, Constantinos C. Tellis, Angeliki Chroni & Alexandros D. Tselepis. (2022) PCSK9 is minimally associated with HDL but impairs the anti-atherosclerotic HDL effects on endothelial cell activation. Journal of Lipid Research 63:10, pages 100272.
Crossref
Fang Jia, Si-Fan Fei, De-Bing Tong, Cong Xue & Jian-Jun Li. (2022) Sex difference in circulating PCSK9 and its clinical implications. Frontiers in Pharmacology 13.
Crossref
Masato Furuhashi, Yu Kataoka, Ryo Nishikawa, Masayuki Koyama, Akiko Sakai, Yukimura Higashiura, Marenao Tanaka, Shigeyuki Saitoh, Kazuaki Shimamoto & Hirofumi Ohnishi. (2022) Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication. Journal of Atherosclerosis and Thrombosis 29:9, pages 1275-1284.
Crossref
Lorenzo Da Dalt & Fabrizia Bonacina. (2022) Metabolic impact of extrahepatic PCSK9 modulation: Extrahepatic PCSK9 modulation. European Atherosclerosis Journal 1:2, pages 41-47.
Crossref
Liu Yang, Yan-Yan Xiao, Liang Shao, Chang-Sheng Ouyang, Yao Hu, Bin Li, Li-Feng Lei & Hong Wang. (2022) Proprotein convertase subtilisin/kexin type 9 inhibitor non responses in an adult with a history of coronary revascularization: A case report. World Journal of Clinical Cases 10:19, pages 6728-6735.
Crossref
Sabina Ugovšek & Miran Šebeštjen. (2022) Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall. Journal of Clinical Medicine 11:13, pages 3625.
Crossref
Yara Azar, Marie-Hélène Gannagé-Yared, Elie Naous, Carine Ayoub, Yara Abou Khalil, Elise Chahine, Sandy Elbitar, Youmna Ghaleb, Catherine Boileau, Mathilde Varret, Petra El Khoury & Marianne Abifadel. (2022) Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren. Metabolites 12:6, pages 504.
Crossref
Paul F. Lebeau, Khrystyna Platko, Jae Hyun Byun, Yumna Makda & Richard C. Austin. (2022) The Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic Diseases. Metabolites 12:3, pages 215.
Crossref
Na-Qiong Wu, Hui-Wei Shi & Jian-Jun Li. (2022) Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review. Frontiers in Cardiovascular Medicine 9.
Crossref
Stefano Ministrini & Federico Carbone. (2022) PCSK9 and Inflammation: Their Role in Autoimmune Diseases, with a Focus on Rheumatoid Arthritis and Systemic Lupus Erythematosus. Current Medicinal Chemistry 29:6, pages 970-979.
Crossref
Emily Punch, Justus Klein, Patrick Diaba‐Nuhoho, Henning Morawietz & Mahdi Garelnabi. (2022) Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis. Journal of the American Heart Association 11:3.
Crossref
Masato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, Yukimura Higashiura, Akiko Sakai, Megumi Matsumoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Koichi Node & Shinichiro Ueda. (2022) Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. Journal of Atherosclerosis and Thrombosis 29:1, pages 24-37.
Crossref
Li Li, Sainan Liu, Jianying Tan, Lai Wei, Dimeng Wu, Shuai Gao, Yajun Weng & Junying Chen. (2022) Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies. Journal of Tissue Engineering 13, pages 204173142210885.
Crossref
Jia Peng, Ming-Ming Liu, Hui-Hui Liu, Yuan-Lin Guo, Na-Qiong Wu, Qian Dong, Jie Qian, Ke-Fei Dou, Cheng-Gang Zhu & Jian-Jun Li. (2021) Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study. Thrombosis Journal 19:1.
Crossref
Jiahui Liu, Fangfang Fan, Xingyu Luo, Wenjun Ji, Yaokun Liu, Yan Zhang & Bo Zheng. (2021) Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine 8.
Crossref
D Matías-Pérez, AD Pérez-Santiago, MA Sánchez Medina, JJ Alpuche Osorno & IA García-Montalvo. (2021) PCSK9 gene participates in the development of primary dyslipidemias . Balkan Journal of Medical Genetics 24:1, pages 5-14.
Crossref
Ye-Xuan Cao, Hui-Hui Liu, Jing-Lu Jin, Di Sun, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Rui-Xia Xu, Jing Sun, Raul D Santos & Jian-Jun Li. (2021) Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia. European Journal of Preventive Cardiology 28:3, pages 272-279.
Crossref
Yanan Guo, Binjie Yan, Yu Gui, Zhihan Tang, Shi Tai, Shenghua Zhou & Xi‐Long Zheng. (2020) Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall. Journal of Cellular Physiology 236:4, pages 2333-2351.
Crossref
Marianne Zeller, Gilles Lambert, Michel Farnier, Maud Maza, Brice Nativel, Luc Rochette, Catherine Vergely & Yves Cottin. (2021) PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction. Nutrition, Metabolism and Cardiovascular Diseases 31:3, pages 880-885.
Crossref
Aleksey M. Chaulin & Dmitry V. Duplyakov. (2020) Biomarkers of acute myocardial infarction: diagnostic and prognostic value. Part 2 (Literature review). Journal of Clinical Practice 11:4, pages 70-82.
Crossref
Jia Peng, Ming-Ming Liu, Jing-Lu Jin, Ye-Xuan Cao, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Qian Dong, Jing Sun, Rui-Xia Xu & Jian-Jun Li. (2020) Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovascular Diabetology 19:1.
Crossref
Ying Tang, Sheng-Lan Li, Jia-Hui Hu, Kai-Jun Sun, Lei-Ling Liu & Dan-Yan Xu. (2020) Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes. Cardiovascular Diabetology 19:1.
Crossref
Qiwen Chen, Guodong Wu, Chuang Li, Xueting Qin, Rui Liu & Mei Zhang. (2019) Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. American Journal of Cardiovascular Drugs 20:4, pages 343-353.
Crossref
Ying Sun, Jing-Qian Zhao, Yue-Ru Jiao, Jian Ren, Yan-Hong Zhou, Li Li & Heng-Chen Yao. (2020) Predictive value of leukocyte telomere length for the severity of coronary artery disease. Personalized Medicine 17:3, pages 175-183.
Crossref
Ye-Xuan Cao, Jing-Lu Jin, Di Sun, Hui-Hui Liu, Yuan-Lin Guo, Na-Qiong Wu, Rui-Xia Xu, Cheng-Gang Zhu, Qian Dong, Jing Sun & Jian-Jun Li. (2019) Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy. Journal of Translational Medicine 17:1.
Crossref
Chongyou Lee, Yuxia Cui, Junxian Song, Sufang Li, Feng Zhang, Manyan Wu, Long Li, Dan Hu & Hong Chen. (2019) Effects of familial hypercholesterolemia-associated genes on the phenotype of premature myocardial infarction. Lipids in Health and Disease 18:1.
Crossref
Ye-Xuan Cao, Bing-Yang Zhou, Di Sun, Sha Li, Yuan-Lin Guo, Cheng-Gang Zhu, Na-Qiong Wu, Ying Gao, Rui-Xia Xu, Geng Liu, Qian Dong & Jian-Jun Li. (2019) Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia. Personalized Medicine 16:6, pages 467-478.
Crossref
Amir Abbas Momtazi-Borojeni, Sarvenaz Sabouri-Rad, Antonio M GottoJrJr, Matteo Pirro, Maciej Banach, Zuhier Awan, George E Barreto & Amirhossein Sahebkar. (2019) PCSK9 and inflammation: a review of experimental and clinical evidence. European Heart Journal - Cardiovascular Pharmacotherapy 5:4, pages 237-245.
Crossref
Yunes Panahi, Mohsen Sadeghi Ghahrodi, Mohsen Jamshir, Mohammad Amin Safarpour, Vanessa Bianconi, Matteo Pirro, Maryam Moshkani Farahani & Amirhossein Sahebkar. (2019) PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography. Clinical Biochemistry.
Crossref
Yuxia Cui, Sufang Li, Feng Zhang, Junxian Song, Chongyou Lee, Manyan Wu & Hong Chen. (2019) Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction. Clinical Cardiology 42:3, pages 385-390.
Crossref
Zhong Zhang, Teng-Fei Wei, Bei Zhao, Zhao Yin, Quan-Xing Shi, Pei-Lin Liu, Li-Feng Liu, Li Liu, Jing-Tao Zhao, Shuai Mao, Meng-Meng Rao, Shou-Li Wang & Yun-Dai Chen. (2019) Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction. Scientific Reports 9:1.
Crossref
Ye-Xuan Cao, Hui-Hui Liu, Sha Li & Jian-Jun Li. (2018) A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels. American Journal of Cardiovascular Drugs 19:1, pages 87-97.
Crossref
Daisuke Nose, Yuhei Shiga, Yoko Ueda, Yoshiaki Idemoto, Kohei Tashiro, Yasusnori Suematsu, Takashi Kuwano, Ken Kitajima, Keijiro Saku & Shin-ichiro Miura. (2018) Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese. Heart and Vessels 34:1, pages 19-28.
Crossref
H.-W. Zhang, X. Zhao, Y.-L. Guo, Y. Gao, C.-G. Zhu, N.-Q. Wu & J.-J. Li. (2018) Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus. Nutrition, Metabolism and Cardiovascular Diseases 28:10, pages 980-986.
Crossref
Ye-Xuan Cao, Hui-Hui Liu, Di Sun, Jing-Lu Jin, Rui-Xia Xu, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Sha Li, Yan Zhang, Jing Sun & Jian-Jun Li. (2018) The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia. Atherosclerosis 277, pages 7-14.
Crossref
Ye-Xuan Cao, Sha Li, Hui-Hui Liu & Jian-Jun Li. (2018) Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 8:9, pages e022348.
Crossref
Yuichi Ikegami, Ikuo Inoue, Kaiji Inoue, Yuichi Shinoda, Shinichiro Iida, Seiichi Goto, Takanari Nakano, Akira Shimada & Mistuhiko Noda. (2018) The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. npj Aging and Mechanisms of Disease 4:1.
Crossref
Ye‐Xuan Cao, Hui‐Hui Liu, Qiu‐Ting Dong, Sha Li & Jian‐Jun Li. (2018) Effect of proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) monoclonal antibodies on new‐onset diabetes mellitus and glucose metabolism: A systematic review and meta‐analysis . Diabetes, Obesity and Metabolism 20:6, pages 1391-1398.
Crossref
Xi Zhao, Hui-Wen Zhang, Sha Li, Yan Zhang, Rui-Xia Xu, Cheng-Gang Zhu, Na-Qiong Wu, Yuan-Lin Guo, Ping Qing, Xiao-Lin Li, Geng Liu, Qian Dong, Jing Sun & Jian-Jun Li. (2017) Association between plasma proprotein convertase subtisilin/kexin type 9 concentration and coronary artery calcification. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 55:1, pages 158-164.
Crossref
Xiao-min Bu, Dong-mei Niu, Jia Wu, Yun-long Yuan, Jia-xi Song & Jun-jun Wang. (2017) Elevated levels of preβ1-high-density lipoprotein are associated with cholesterol ester transfer protein, the presence and severity of coronary artery disease. Lipids in Health and Disease 16:1.
Crossref
Markella V Zanni, Lauren A Stone, Mabel Toribio, Dodie E Rimmelin, Jake Robinson, Tricia H Burdo, Kenneth Williams, Kathleen V Fitch, Janet Lo & Steven K Grinspoon. (2017) Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. Open Forum Infectious Diseases 4:4.
Crossref
Paul A. Gurbel, Eliano P. Navarese & Udaya S. Tantry. (2017) Exploration of PCSK9 as a Cardiovascular Risk Factor. Journal of the American College of Cardiology 70:12, pages 1463-1466.
Crossref
Zhi-Han Tang, Juan Peng, Zhong Ren, Jing Yang, Ting-Ting Li, Tao-Hua Li, Zuo Wang, Dang-Heng Wei, Lu-Shan Liu, Xi-Long Zheng & Zhi-Sheng Jiang. (2017) New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway. Atherosclerosis 262, pages 113-122.
Crossref
Sha Li, Na-Qiong Wu, Cheng-Gang Zhu, Yan Zhang, Yuan-Lin Guo, Ying Gao, Xiao-Lin Li, Ping Qing, Chuan-Jue Cui, Rui-Xia Xu, Jing Sun, Geng Liu, Qian Dong & Jian-Jun Li. (2017) Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis 260, pages 67-74.
Crossref
Sha Li, Yuan-Lin Guo, Xi Zhao, Yan Zhang, Cheng-Gang Zhu, Na-Qiong Wu, Rui-Xia Xu, Ping Qing, Ying Gao, Xiao-Lin Li, Jing Sun, Geng Liu, Qian Dong & Jian-Jun Li. (2017) Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity. Scientific Reports 7:1.
Crossref
Sha Li, Xi Zhao, Yan Zhang, Cheng-Gang Zhu, Yuan-Lin Guo, Na-Qiong Wu, Rui-Xia Xu, Ping Qing, Ying Gao, Jing Sun, Geng Liu, Qian Dong & Jian-Jun Li. (2016) Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C. Oncotarget 8:7, pages 12333-12341.
Crossref
Sha Li, Yan Zhang, Cheng-Gang Zhu, Yuan-Lin Guo, Na-Qiong Wu, Ying Gao, Ping Qing, Xiao-Lin Li, Jing Sun, Geng Liu, Qian Dong, Rui-Xia Xu, Chuan-Jue Cui & Jian-Jun Li. (2016) Identification of familial hypercholesterolemia in patients with myocardial infarction: A Chinese cohort study. Journal of Clinical Lipidology 10:6, pages 1344-1352.
Crossref
Rodrigo Alonso, Pedro Mata, Ovidio Muñiz, Francisco Fuentes-Jimenez, Jose Luis Díaz, Daniel Zambón, Marta Tomás, Cesar Martin, Thomas Moyon, Mikaël Croyal, Aurélie Thedrez & Gilles Lambert. (2016) PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. Atherosclerosis 254, pages 249-253.
Crossref
Charalambos Vlachopoulos, Dimitrios Terentes-Printzios, Georgios Georgiopoulos, Ioannis Skoumas, Iosif Koutagiar, Nikolaos Ioakeimidis, Christodoulos Stefanadis & Dimitrios Tousoulis. (2016) Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis. Atherosclerosis 252, pages 50-60.
Crossref
Wen-guang Wang, Yong-feng He, Yuan-li Chen, Fu-mei Zhao, Yan-qiu Song, Hong Zhang, Yan-he Ma, Xin Guan, Wen-ya Zhang, Xiao-lin Chen, Chao Liu & Hong-liang Cong. (2016) Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification: A prospective, cross sectional study. Journal of International Medical Research 44:4, pages 865-874.
Crossref
Sheng-Hua Yang, Ying Du, Sha Li, Yan Zhang, Rui-Xia Xu, Cheng-Gang Zhu, Yuan-Lin Guo, Na-Qiong Wu, Qian Dong, Jing Sun & Jian-Jun Li. (2016) Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima–media thickness in hypertensives. Hypertension Research 39:8, pages 598-605.
Crossref
S.-H. Yang, S. Li, Y. Zhang, R.-X. Xu, C.-G. Zhu, Y.-L. Guo, N.-Q. Wu, P. Qing, Y. Gao, C.-J. Cui, Q. Dong, J. Sun & J.-J. Li. (2016) Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese. Journal of Endocrinological Investigation 39:8, pages 875-883.
Crossref
Eliano P. Navarese, Michalina Kołodziejczak, Dimitrios Dimitroulis, Georg Wolff, Hans L. Busch, Fiorella Devito, Alessandro Sionis & Marco Matteo Ciccone. (2016) From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications. European Heart Journal - Cardiovascular Pharmacotherapy 2:1, pages 44-53.
Crossref
Jian-Jun Li, Sha Li, Yan Zhang, Rui-Xia Xu, Yuan-Lin Guo, Cheng-Gang Zhu, Na-Qiong Wu, Ping Qing, Ying Gao, Jing Sun, Geng Liu & Qian Dong. (2015) Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease. Medicine 94:52, pages e2426.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.